Article info
PDFLaboratory science
The tellurium redox immunomodulating compound AS101 inhibits IL-1β-activated inflammation in the human retinal pigment epithelium
- Correspondence to Dr Robert B Nussenblatt, Laboratory of Immunology, National Eye Institute, National Institutes of Health, Building 10, Room 10N109, 10 Center Drive, Bethesda, MD 20892, USA; drbob{at}nei.nih.gov
Citation
The tellurium redox immunomodulating compound AS101 inhibits IL-1β-activated inflammation in the human retinal pigment epithelium
Publication history
- Received April 19, 2012
- Revised February 12, 2013
- Accepted March 20, 2013
- First published April 27, 2013.
Online issue publication
March 22, 2016
Article Versions
- Previous version (22 March 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions